Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mathurin Fumery

Showing results (141-150 of 254) with videos related to

Pageof 26
Sort By:
Journal of Clinical Medicine|October 21, 2020
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real LifeValentine Deprez, Laure Le Monnier, Jean-Marc Sobhy-Danial, et al.
Gut|May 31, 2019
Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's diseaseHarry Sokol, Loic Brot, Carmen Stefanescu, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based StudyDana Duricova, Ariane Leroyer, Guillaume Savoye, et al.
BMC Gastroenterology|December 2, 2022
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
BMC Gastroenterology|February 2, 2023
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
The Lancet Regional Health. Europe|October 31, 2024
Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based studyHélène Sarter, Thibaut Crétin, Guillaume Savoye, et al.
Carcinogenesis|July 12, 2013
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγChristel Rousseaux, Noura El-Jamal, Mathurin Fumery, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 7, 2019
Long-term outcome of pediatric-onset Crohn's disease: A population-based cohort studyMathurin Fumery, Benjamin Pariente, Helene Sarter, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 29, 2019
Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysisMathurin Fumery, Marion Tilmant, Clara Yzet, et al.
Inflammatory Bowel Diseases|November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 YearsGilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Pageof 26

Showing results (141-150 of 254) with videos related to

Sort By:
Pageof 26
Journal of Clinical Medicine|October 21, 2020
Therapeutic Maintenance of Baricitinib and Tofacitinib in Real LifeValentine Deprez, Laure Le Monnier, Jean-Marc Sobhy-Danial, et al.
Gut|May 31, 2019
Prominence of ileal mucosa-associated microbiota to predict postoperative endoscopic recurrence in Crohn's diseaseHarry Sokol, Loic Brot, Carmen Stefanescu, et al.
Journal of Crohn'S & Colitis|October 6, 2017
Extra-intestinal Manifestations at Diagnosis in Paediatric- and Elderly-onset Ulcerative Colitis are Associated With a More Severe Disease Outcome: A Population-based StudyDana Duricova, Ariane Leroyer, Guillaume Savoye, et al.
BMC Gastroenterology|December 2, 2022
Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
BMC Gastroenterology|February 2, 2023
Correction: Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective studyCassandra Rayer, Maria Nachury, Arnaud Bourreille, et al.
The Lancet Regional Health. Europe|October 31, 2024
Incidence, prevalence and clinical presentation of inflammatory bowel diseases in Northern France: a 30-year population-based studyHélène Sarter, Thibaut Crétin, Guillaume Savoye, et al.
Carcinogenesis|July 12, 2013
The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARγChristel Rousseaux, Noura El-Jamal, Mathurin Fumery, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 7, 2019
Long-term outcome of pediatric-onset Crohn's disease: A population-based cohort studyMathurin Fumery, Benjamin Pariente, Helene Sarter, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|January 29, 2019
Premedication as primary prophylaxis does not influence the risk of acute infliximab infusion reactions in immune-mediated inflammatory diseases: A systematic review and meta-analysisMathurin Fumery, Marion Tilmant, Clara Yzet, et al.
Inflammatory Bowel Diseases|November 16, 2016
Costs of Crohn's Disease According to Severity States in France: A Prospective Observational Study and Statistical Modeling over 10 YearsGilles Boschetti, Stephane Nancey, Fady Daniel, et al.
Pageof 26